Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XE26
|
| gptkbp:brand |
gptkb:Cabometyx
gptkb:Cometriq |
| gptkbp:CASNumber |
1140909-48-3
|
| gptkbp:chemicalFormula |
C28H24FN3O5
|
| gptkbp:developer |
gptkb:Exelixis
|
| gptkbp:eliminationHalfLife |
99 hours
|
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
cabozantinib citrate
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits multiple receptor tyrosine kinases
|
| gptkbp:metabolism |
liver (CYP3A4)
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:palmar-plantar_erythrodysesthesia
nausea diarrhea fatigue hypertension decreased appetite |
| gptkbp:usedFor |
treatment of hepatocellular carcinoma
treatment of medullary thyroid cancer treatment of renal cell carcinoma |
| gptkbp:bfsParent |
gptkb:Cometriq
|
| gptkbp:bfsLayer |
7
|